ABT-737, an inhibitor of Bcl-2, induces apoptosis in MCs and decreases the levels of AD-related biomarkers, including IgE, histamine, TSLP, and inflammatory cytokines in vitro, reducing AD-like clinical symptoms in an AD mouse model [192]. This evidence concerns the gene BCL2 and Alzheimer disease.